(Q42811812)

English

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models

scientific article published on 11 October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

1 reference

based on heuristic

inferred from title

13

object named as

Len Neckers

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

8

object named as

Jane B Trepel

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Carole Sourbier

3

object named as

Carole Sourbier

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

4

object named as

Kristin Beebe

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

author name string

Naoto Miyajima

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Shinji Tsutsumi

2

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Mehdi Mollapour

5

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Candy Rivas

6

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Soichiro Yoshida

7

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Ying Huang

9

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Manabu Tatokoro

10

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Nobuo Shinohara

11

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Katsuya Nonomura

12

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

language of work or name

0 references

publication date

11 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

7022-7033

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activating mutations for the met tyrosine kinase receptor in human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel germ line juxtamembrane Met mutation in human gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hsp90 Recognizes a Common Surface on Client Kinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting MET in cancer: rationale and progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hsp90 increases LIM kinase activity by promoting its homo-dimerization.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting Hsp90: small-molecule inhibitors and their clinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of Akt kinase activity by binding to Hsp90

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Met, metastasis, motility and more

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hsp90 molecular chaperone inhibitors: are we there yet?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24121490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/0008-5472.CAN-13-1156

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42811812&oldid=2140782923"